Interleukin-9 aggravates doxorubicin-induced cardiotoxicity by promoting inflammation and apoptosis in mice. 2020

Di Ye, and Zhen Wang, and Yao Xu, and Jing Ye, and Menglong Wang, and Jianfang Liu, and Jishou Zhang, and Mengmeng Zhao, and Jiangbin Chen, and Jun Wan
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan, China.

OBJECTIVE Interleukin (IL) 9 is a pleiotropic cytokine, and recent studies have demonstrated that IL-9 is associated with several cardiovascular diseases, via regulation of the inflammatory response. Doxorubicin (DOX) is known to induce severe cardiac injury and dysfunction by enhancing inflammation. This study aimed to investigate the role of IL-9 in DOX-induced cardiotoxicity. METHODS DOX was used to induce cardiac dysfunction and the expression of IL-9 in the murine cardiac tissues was measured. The mice were intraperitoneally injected with recombinant mouse IL-9 (rmIL-9) or anti-IL-9 neutralizing antibody (IL-9nAb) for investigating the effect of IL-9 on DOX-induced cardiac injury and dysfunction. The messenger ribonucleic acid (mRNA) expression levels of the pro-inflammatory cytokines were determined in each group by quantitative real-time polymerase chain reaction (RT-qPCR). The effect of rmIL-9 or IL-9nAb on DOX-induced apoptosis was determined both in vivo and vitro. RESULTS IL-9 levels significantly increased in the heart following DOX injection. Cardiac injury and dysfunction were induced by DOX, and treatment with IL-9nAb significantly alleviated DOX-induced injury, whereas rmIL-9 administration aggravated the cardiac damage. IL-9nAb decreased the expression of pro-inflammatory cytokines in the DOX-treated mice, while rmIL-9 administration increased the levels of pro-inflammatory cytokines. IL-9nAb reduced DOX-induced myocardial apoptosis, whereas rmIL-9 administration produced the opposite results. Additionally, IL-9nAb mitigated the DOX-induced apoptosis in H9C2 cells, while administration of rmIL-9 produced the opposite effect. CONCLUSIONS Our results demonstrated that IL-9 aggravated DOX-induced cardiac injury and dysfunction by promoting the inflammatory response and cardiomyocyte apoptosis.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D016906 Interleukin-9 A multifunctional cytokine secreted by primarily by activated TH2 CELLS that may play a role as a regulator of allergic INFLAMMATION. It has been shown to enhance the growth and CELL DIFFERENTIATION of MAST CELLS, and can act on a variety of other immune cells. IL-9,P40 T-Cell Growth Factor,T-Cell Growth Factor P40,IL9,Interleukin 9,P40 T Cell Growth Factor,T Cell Growth Factor P40
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Di Ye, and Zhen Wang, and Yao Xu, and Jing Ye, and Menglong Wang, and Jianfang Liu, and Jishou Zhang, and Mengmeng Zhao, and Jiangbin Chen, and Jun Wan
June 2013, Cardiovascular research,
Di Ye, and Zhen Wang, and Yao Xu, and Jing Ye, and Menglong Wang, and Jianfang Liu, and Jishou Zhang, and Mengmeng Zhao, and Jiangbin Chen, and Jun Wan
January 2022, Evidence-based complementary and alternative medicine : eCAM,
Di Ye, and Zhen Wang, and Yao Xu, and Jing Ye, and Menglong Wang, and Jianfang Liu, and Jishou Zhang, and Mengmeng Zhao, and Jiangbin Chen, and Jun Wan
January 1993, Biotherapy (Dordrecht, Netherlands),
Di Ye, and Zhen Wang, and Yao Xu, and Jing Ye, and Menglong Wang, and Jianfang Liu, and Jishou Zhang, and Mengmeng Zhao, and Jiangbin Chen, and Jun Wan
January 2023, Evidence-based complementary and alternative medicine : eCAM,
Di Ye, and Zhen Wang, and Yao Xu, and Jing Ye, and Menglong Wang, and Jianfang Liu, and Jishou Zhang, and Mengmeng Zhao, and Jiangbin Chen, and Jun Wan
May 2018, Redox biology,
Di Ye, and Zhen Wang, and Yao Xu, and Jing Ye, and Menglong Wang, and Jianfang Liu, and Jishou Zhang, and Mengmeng Zhao, and Jiangbin Chen, and Jun Wan
January 2002, Molecular and cellular biochemistry,
Di Ye, and Zhen Wang, and Yao Xu, and Jing Ye, and Menglong Wang, and Jianfang Liu, and Jishou Zhang, and Mengmeng Zhao, and Jiangbin Chen, and Jun Wan
November 2021, Archives of biochemistry and biophysics,
Di Ye, and Zhen Wang, and Yao Xu, and Jing Ye, and Menglong Wang, and Jianfang Liu, and Jishou Zhang, and Mengmeng Zhao, and Jiangbin Chen, and Jun Wan
January 2022, American journal of cancer research,
Di Ye, and Zhen Wang, and Yao Xu, and Jing Ye, and Menglong Wang, and Jianfang Liu, and Jishou Zhang, and Mengmeng Zhao, and Jiangbin Chen, and Jun Wan
November 2022, Bioscience, biotechnology, and biochemistry,
Di Ye, and Zhen Wang, and Yao Xu, and Jing Ye, and Menglong Wang, and Jianfang Liu, and Jishou Zhang, and Mengmeng Zhao, and Jiangbin Chen, and Jun Wan
July 2020, Clinical and translational medicine,
Copied contents to your clipboard!